Summary: There is no authorised UK reconstitution ratio for retatrutide, as it remains an unlicensed investigational compound with no approved MHRA guidance, SmPC, or NHS prescribing pathway
Measurements using body composition methods (DEXA, bioimpedance, caliper) are more informative than scale weight alone, as AOD-9604 may preserve lean tissue while selectively reducing fat mass
Eli Lilly continues to advance the clinical development program with results expected in the coming years
NAD+ is administered via at-home injections as part of a personalized plan
Research examines its effects on NNMT activity, NAD+ homeostasis, metabolic pathway utilization, energy expenditure, and adipose-tissue endpoints independent of feeding-behavior changes
Last accessed: September 2024